Teva's Generic Exclusivity For Cozaar/Hyzaar Is Upheld By District Court; Apotex Appeals
This article was originally published in The Pink Sheet Daily
Executive Summary
Court finds that FDA correctly followed an appeals court's reasoning in awarding Teva exclusivity; Apotex says the agency failed to make a distinction between patent delisting and expiration.
You may also be interested in...
FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.
Teva Launches Generic Cozaar/Hyzaar With Market Exclusivity As FDA Seeks Court Action To Permit Other Entrants
Teva's skirmish with FDA has paid off. The company launched generic versions of Merck's top-selling hypertension drugs Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide) on April 6 with 180 days of marketing exclusivity
Teva Launches Generic Cozaar/Hyzaar With Market Exclusivity As FDA Seeks Court Action To Permit Other Entrants
Teva's skirmish with FDA has paid off. The company launched generic versions of Merck's top-selling hypertension drugs Cozaar (losartan) and Hyzaar (losartan/hydrochlorothiazide) on April 6 with 180 days of marketing exclusivity